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Incidence of Candida albicans vaginitis has been increasing since a significant num-
ber of women suffer from acute episodes, and recurrent infection may frequently occur
after therapy (1). It has been estimated that 75% of all women will experience a vaginal
candidiasis once in their lifetime, with up to 5% suffering from recurrent vaginal can-
didiasis (2). From such a perspective, topical treatment of candida vaginitis could be a
rational choice for management of localized infection, while systemic therapy could be
limited to patients proven to be nonresponsive or intolerant to intravaginally administe-
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In this study, a bioadhesive dosage form of clotrimazole
was designed using a combination of bioadhesive poly-
mers Carbopol 934P, sodium carboxymethyl cellulose and
sodium alginate in different ratios. The bioadhesive strength
was evaluated by measuring the force required to detach
the tablets from porcine vaginal mucosal membrane. The
strong interaction between polymer and mucus lining of
the tissue helps increase the contact time and permits lo-
calization of activity. Carbopol 934P showed maximum
bioadhesion and required maximum force for detachment;
the force required for detachment was directly proporti-
onal to its content. The formulations were tested for their
swelling behavior using the agar gel plate method. The
swelling index was a function of the concentration of the
hydrophilic polymer and the formulations containing
Carbopol 934P and sodium carboxymethyl cellulose were
found to swell to a greater extent than those containing
Carbopol and sodium alginate. In vitro release studies
showed that the batch consisting of 2:1 ratio of Carbopol
934P/sodium alginate (batch C3) released clotrimazole
over 24 h. The similarity factor showed that the dissolu-
tion profiles of fresh and aged tablets were similar, sug-
gesting good stability of vaginal tablets prepared using a
combination of Carbopol 934P and sodium alginate.
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bopol 934P, sodium alginate, sodium carboxymethyl cel-
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red drugs. Although antimycotic agents such as broad spectrum imidazole derivatives
are now available for topical short-term therapy (3, 4), intravaginally delivered drugs
may fail to achieve high concentration at the site of infection due to their fairly prompt
removal from the vaginal compartment through physiological secretions (5). Conventi-
onal delivery systems such as creams, foams, gels, tablets, irrigations or pessaries might
not ensure sufficient therapeutic efficacy because of their short residence time due to the
self-cleansing action of the vaginal tract (6–8). Therefore, it can be envisaged that high
concentration at the site of infection could be achieved by the use of a bioadhesive poly-
mer that can interact with the mucosa and can hold the delivery system in the vaginal
tract for a few days without any toxic effects or important physiological modifications
(9, 10).
Clotrimazole is a broad-spectrum antimycotic agent effective against pathogenic der-
matophytes, yeasts and several species of Candida, Trichophyton, Microsporum, Epidermo-
phyton and Malassezia. Oral bioavailability of clotrimazole is poor and it has a high inci-
dence of gastrointestinal disorders and neurological reactions. However, clotrimazole is
known to be very effective locally and causes no major side effects (11).
Local concentrations of econazole, miconazole, estriol or iodine in vagina are re-
ported to be sustained using combinations of polycarbophil and semisynthetic triglycer-
ides or polyethyleneglycol (12). Polycarbophil or carbopol have been also combined with
hydroxypropyl cellulose, hydroxyethyl cellulose and HPMC (13) for modulating the bio-
adhesive strength and drug release from bioadhesive tablets. It is essential to partly sub-
stitute polycarbophil or carbopol by other polymers in order to decrease their inherently
high bioadhesive strength that might damage the vaginal mucus membrane (14). The
present investigation was aimed at formulating vaginal tablets by employing various
combinations of Carbopol 934P and sodim carboxymethyl cellulose or sodium alginate




Clotrimazole (CLT) was received as a gift sample from Ranbaxy Research Labs., In-
dia. Carbopol 934P (CP) was a gift sample from Ind. Swift Laboratories Limited, India.
Sodium alginate, sodium carboxymethyl cellulose (NaCMC) and magnesium stearate were
purchased from SD Fine Chemicals Ltd., India, agar powder and dioxane were purchas-
ed from Hi-Media Labs Pvt. Ltd, India and E. Merck Ltd., India, respectively. Ammo-
nium actetate and glacial acetic acid were purchased from CDH Pvt. Ltd., India. All re-
agents and chemicals were of analytical grade and used as received.
Preparation of bioadhesive tablets
Each tablet contained a constant mass of CLT (100 mg) and magnesium stearate (10
mg) and a varying composition of a bioadhesive polymer mixture of either CP or NaCMC
or CP and sodium alginate (Table I). All materials were passed through a 125-m sieve
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and retained on a 90-m sieve. CLT was first mixed with the bioadhesive polymer mix-
ture for 10 min. Magnesium stearate was then added and mixing was continued for an-
other 10 min. Tablets of approximate mass of 1 g were produced by direct compression
of this mixture.
Evaluation of bioadhesive tablets
The formulated tablets (10 in number) of each batch were evaluated for hardness
using the Monsanto hardness tester (Tab Machines, India). Friability was determined ac-
cording to the procedure mentioned in USP 28 (15). Mass variation of the formulated
tablets (20 in number) was tested in accordance with the procedures given in Indian
Pharmacopoeia (16). The swelling rate of bioadhesive tablets was evaluated by using a 1%
agar gel plate at 37 C (17).
In situ bioadhesive strength
Bioadhesive strength of the tablets was measured by a method reported by Gupta et
al. (18). Porcine vaginal mucosa was used as a model membrane and acetate buffer, pH
6.0 as moistening fluid for measurement of bioadhesive strength. The surface of the mu-
cosal membrane was first blotted with a filter paper and then moistened with 25 L of
acetate buffer. The force required to detach the tablet from the mucosal surface was tak-
en as the measure of bioadhesive strength. The thickness of the vaginal mucosal mem-
brane was 0.01–0.05 mm and the temperature was maintained at 37 °C throughout the
study. Each experiment was performed using porcine vaginal mucosa obtained from
three different animals.
Vaginal mucosa was obtained within 1 h of sacrificing female pigs at the local sla-
ughter house. The age (mean ± SD) of female pigs was 1.5 ± 0.5 years.
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Total mass of CP alone, NaCMC alone, sodium alginate alone or combination of CP and NaCMC or CP and
sodium alginate was 900 mg in all the formulations.
Dissolution rate
The in vitro dissolution studies were carried out using the USP 28 (15) type 5-paddle
method. The dissolution medium contained a 65:35 ratio of 0.1 mmol L–1 acetate buffer
pH 6.0 and dioxane (19). The medium was maintained at 37 ± 1 °C and was stirred at
100 rpm. Samples (3 mL) withdrawn at suitable time intervals were compensated with
fresh dissolution medium and assayed spectrophotometrically at 270 nm. It was made
clear that none of the ingredients used in the matrix formulation interfered with the as-
say. Each experiment was performed in triplicate.
CLT release kinetics
The release kinetics of CLT from prepared bioadhesive tablets was evaluated by em-
ploying the Peppas and Sahlin equation (20): Mt/M∝ = k tn, where Mt is the amount of
the drug released at time t, M∝ is the amount of the drug released after infinite time, k is
the kinetic constant incorporating structural and geometric characteristics of the tablet
and n is the diffusional exponent indicative of the mechanism of drug release.
Stability studies
The selected formulation containing a CP/sodium alginate 2:1 ratio (batch C3) was
subjected to accelerated storage conditions (40 ± 2 °C/75 ± 5% RH for 6 months). The
formulation was analyzed for organoleptic characteristics, hardness and dissolution. Si-
milarity factor f2 was calculated to compare the dissolution profiles according to equa-
tion (21):








=∑n R Tt tt
n
Tt and Rt are the percent drug dissolved at each time point for test and reference. Three
tablets were subjected to this study.
RESULTS AND DISCUSSION
The average mass of vaginal tablets (Table II) was found to range from 975 to 995
mg exhibiting a mass of 985 ± 6 mg (mean ± SD). Tablets of all batches complied with
the mass variation requirement of Indian Pharmacopoeia (16); tablets of no batch varied
more than 5% of the average mass. Average hardness of tablets belonging to various
batches (Table II) indicated good strength. Sufficient strength of all tablets was also evi-
dent since the friability was less than 1% (m/m), indicating compliance with the require-
ments of USP 28 (15). Vaginal tablets formulated using maximum amount of CP (batch
A) required the greatest force to be detached them from the pig vaginal membrane (Tab-
le II). The force required for detaching these tablets was, respectively, 3-fold and 5-fold
greater than that required for tablets containing an equivalent amount of NaCMC (batch
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B1) or sodium alginate (batch C1). This indicated a superior bioadhesive property of CP
compared to NaCMC or sodium alginate. The bioadhesive property of CP is reported to
be due to carboxyl groups present on its acrylic acid backbone, which possess an ability
to interact with sialic acid molecules present in the mucus layer (22). Replacement of CP
with increasing amounts of NaCMC in tablet formulations produced tablets that exhibit-
ed greater bioadhesive strength than those prepared with NaCMC alone. The force re-
quired to detach tablets formulated using CP/NaCMC ratios of 2.25:0.75 (batch B2), 2:1
(batch B3), or 1:2 (batch B4) was, respectively, 0.9-fold, 0.7-fold and 0.5-fold lower than
that required for tablets prepared by using CP alone. Similarly, tablets prepared by using
CP/sodium alginate ratios of 2.25:0.75 (batch C2), 2:1 (batch C3), or 1:2 (batch C4) re-
quired, respectively, 0.8-fold, 0.6-fold and 0.4-fold lower force in vitro to be detached
from the porcine vaginal membrane as compared to tablets prepared with CP only. Fur-
thermore, data summarized in Table II indicate lower bioadhesive strength of tablets
prepared by using combinations of CP and sodium alginate (batches C2-C4) compared
to those prepared by using similar combinations of CP and NaCMC (batches B2-B4).
This seems to be due to lower bioadhesive strength of sodium alginate than that of NaCMC
(23). These results indicate that the inherently high bioadhesive strength of Carbopol 934P
could be modified by partly substituting its content with NaCMC or sodium alginate.
Swelling index of various vaginal formulations is summarized in Table II. Tablets
containing CP alone (batch A) exhibited the lowest swelling index, suggesting the least
water uptake whereas those containing NaCMC alone (batch B1) or sodium alginate alo-
ne (batch C1) gelled to such an extent that their swelling index could not be determined.
This appears to be due to excessive water uptake by tablets prepared by using NaCMC
or sodium alginate alone. A comparison of the tablets prepared by using 2.25:0.75, 2:1, or
1:2 ratios of CP/NaCMC (batches B2-B4) showed an increase in the swelling index. A si-
milar trend was also found when similar ratios of CP/sodium alginate were used
(batches C2-C4). However, the swelling index of tablets containing various ratios of CP/
sodium alginate was lower than that of tablets containing similar ratios of CP/NaCMC.
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Each value represents mean ± SD: a n = 20, b n = 3.
– Swelling could not be measured.
The observed difference in the swelling behaviour of these tablets could be attributed to
greater hydrophilic nature of NaCMC. The swelling index of CP is reported to be less
than that of NaCMC (23). Further, the swelling index of sodium alginate is reported to
be less than that of NaCMC (25). Hence, the observed swelling index of tablets appears
to be predominantly governed by the presence of NaCMC or sodium alginate. Swelling
of the polymer has been reported to help in the interpenetration of mucus and polymer,
making bioadhesion possible (26). Therefore the formulations containing NaCMC can be
expected to possess a better bioadhesive character.
It is evident from Figs. 1a and 1b that the release of CLT was slower from tablets
confirming combinations of CP and NaCMC (batches B2-B4) as compared to those con-
taining different ratios of CP and sodium alginate (batches C2-C4). An increase in the
thickness of the diffusional path length due to higher relaxation of the cellulosic chains
in tablets containing NaCMC seems to be responsible for slowing down the release of
CLT (26). Tablets formulated using CP alone (batch A) and those prepared using a mix-
ture of 2.25:0.75 of CP/NaCMC (batch B2) or CP/sodium alginate (batch C2) released
99% of CLT in 18 h. On the other hand, tablets prepared using a mixture of CP and
NaCMC in the ratio of 2:1 (batch B3) or 1:2 (batch B4) released 94% and 85% CLT, respec-
tively, in 24 h. Tablets formulated with 1:2 ratio of a mixture of CP/sodium alginate
(batch C4) released 90% of CLT over 24 h. Complete release (100%) of CLT over 24 h was
observed in tablets prepared using a 2:1 mixture of CP/sodium alginate (batch C3). It is
well known that NaCMC possesses excessive swelling behaviour. Hence faster release of
CLT from tablets containing a combination of CP and sodium alginate (Fig. 2) as com-
pared to that from tablets containing combinations of CP and NaCMC can be ascribed to
relatively lower swelling properties of sodium alginate (25). Therefore, dissolved CLT
molecules can easily cross the narrow diffusional barrier formed due to the presence of
CP and sodium alginate.
Irrespective of the ratio of CP/NaCMC or CP/sodium alginate, a zero order release
of CLT was observed in all tablet formulations. Application of Peppas and Sahlin equa-
tion (20) to CLT release data of tablets prepared with various combinations of CP and
NaCMC or CP and sodium alginate revealed that the value of n, the diffusional expo-
nent of in vitro release ranged from 0.5 to 0.8. This indicated that zero order release from
vaginal tablets was due to a combination of diffusion and chain relaxation mechanism
being operative during drug release from all formulated vaginal tablets.
The tablets prepared with a 2:1 mixture of CP/sodium alginate (batch C3) released
100% of CLT over 24 h, suggesting their suitability for once a day administration. These
tablets showed no change in physical characteristics and drug release profile when sub-
jected to accelerated stability studies. A comparison of CLT release profiles of fresh and
aged tablets showed a f2 value of 66. f2 values ranging between 50 to 100 are reported to
indicate similar drug release profiles (21). Hence, the tablets prepared using a 2:1 mix-
ture of CP/sodium alginate can be an effective and stable once a day formulation for va-
ginal conditions.
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CONCLUSIONS
Use of bioadhesive polymers for vaginal drug delivery offers the advantage of sus-
tained effect in the vagina. The results of the present investigation indicate that the in-
herently high bioadhesive strength of CP could be suitably modified by addition of sodium
alginate. The tablets containig a 2:1 mixture of CP/sodium alginate (batch C3) slowly re-
leased 99% CLT over 24 h. These tablets are expected to offer a patient compliant once-
-a-day vaginal bioadhesive formulation for sustained local effect of CLT in vaginal can-
didiasis.
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Fig. 1. CLT release profiles in vitro of vaginal tablets formulated using a) CP only (A), and various
ratios of CP/NaCMC, (B2: 2.25:0.75, B3: 2:1 and B4: 1:2) and b) various ratios of CP/sodium algi-
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S A @ E T A K
Bioadhezivne vaginalete s klotrimazolom: priprava i evaluacija
GARIMA SHARMA, S. JAIN, A. K. TIWARY i GURPREET KAUR
U radu je opisana priprava bioadhezivnih vaginaleta s klotrimazolom, kombinaci-
jom nekoliko bioadhezivnih polimera u razli~itim omjerima (Carbopol 934P, natrijeva sol
karboksimetilceluloze i natrijev alginat). Bioadhezivnost je odre|ena mjerenjem sile koja
je potrebna za odvajanje tablete s vaginalne mukozne membrane svinje. Zbog jake in-
terakcije izme|u polimera i mukoze produljilo se vrijeme kontakta pripravka s ko`om i
lokaliziralo se djelovanje lijeka. Maksimum bioadhezije postignut je uz Carbopol 934P, a
sila potrebna za odvajanje pripravka bila je proporcionalna njegovom udjelu. Priprav-
cima je ispitana sposobnost bubrenja pomo}u metode s agarnim plo~ama. Indeks bubrenja
ovisio je o koncentraciji hidrofilnog polimera. Pripravci s karbopolom i karboksimetil-
celulozom ja~e su bubrili od pripravaka s karbopolom i natrijevim alginatom. In vitro
ispitivanja pokazala su da se iz pripravaka s omjerom karbopola i natrijevog alginata 2:1
(pripravak C3) osloba|ao klotrimazol tijekom 24 h. Profil osloba|anja bio je sli~an iz
svje`e pripravljenih i starih vaginaleta, {to ukazuje na njihovu stabilnost.
Klju~ne rije~i: bioadhezivi, vaginalne tablete, klotrimazol, Carbopol 934P, natrijev alginat, natrijeva
sol karboksimetilceluloze
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